Compare Incyte Corporation (INCY) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Norfolk Southern Corporation — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Norfolk Southern Corporation trades at $335.33 (market cap $75.23B). The key difference: Norfolk Southern Corporation is far larger — about 3.3× Incyte Corporation's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NSC | |
|---|---|---|
Market Cap | $23.11B | $75.23B |
Sector | Health | Technology |
52-Week High | $118.52 | $340.16 |
52-Week Low | $67.38 | $272.35 |
Enterprise Value | $19.13B | $90.99B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Norfolk Southern (NSC) trades at $334.97, down 1.53% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the pending merger with Union Pacific and upcoming Q2 2026 earnings on July 23, 2026.
The stock offers a moderate upside to the $344.40 consensus price target, supported by earnings momentum and cost controls, but faces risks from regulatory scrutiny of the merger and rich valuations. Investor sentiment is mixed amid merger uncertainties and high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
